Literature DB >> 19356375

Geographical prevalence, risk factors and impact of hepatitis B and C after renal transplantation.

V Kliem1, U Michel, M Burg, A Bock, J Chapman, B Dussol, L Fritsche, Y Lebranchu, F Oppenheimer, E Pohanka, M Salvadori, G Tufveson.   

Abstract

BACKGROUND: Hepatitis B (HBV) and hepatitis C (HCV) virus infections are major risk factors affecting long-term morbidity and mortality after renal transplantation. Hepatitis prevalence is subject to geographical variations.
OBJECTIVE: To compare and analyze the geographical prevalence, risk factors and impact of HBV and HCV infection in multinational cohorts of renal transplant recipients.
METHODS: From 1989 - 2002, data on 12,856 kidney transplant recipients in 37 countries were collected within the prospective MOST (Multinational Observational Study in Transplantation). Subgroup analyses of hepatitis-related prevalence, risk factors and impact were conducted on patients whose HBV and HCV status was available at time of transplantation. Countries were substratified according to population prevalence of > or = 5% HBV or > or = 10% HCV.
RESULTS: The prevalence of HBV was 2.9%, of HCV 8.7% and of HBV together with HCV 0.4%. Risk factors for hepatitis infection in renal transplant recipients were long dialysis time, retransplantation and blood transfusions. At each study endpoint up to 5 years after transplantation, no significant differences in graft function were observed, although the 1-year acute rejection rate tended to be lower in HCV+ patients. At 5 years post-transplant, there were no differences between the subgroups and regions regarding infections, post-transplant diabetes mellitus or malignancies including PTLD.
CONCLUSIONS: Overall, HCV infections are more prevalent than HBV. Despite large geographical differences in prevalence, HBV and HCV status did not appear to have a significant impact on renal graft function, infections, malignancies and post-transplant diabetes mellitus up to 5 years after renal transplantation throughout the MOST countries.

Entities:  

Mesh:

Year:  2009        PMID: 19356375     DOI: 10.5414/cnp71423

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  3 in total

1.  Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups.

Authors:  Annunziata Faustini; Paola Colais; Emanuele Fabrizi; Anna Maria Bargagli; Marina Davoli; Domenico Di Lallo; Anteo Di Napoli; Patrizio Pezzotti; Chiara Sorge; Rita Grillo; Carla Maresca; Olga Recchia; Carlo A Perucci
Journal:  BMC Infect Dis       Date:  2010-04-19       Impact factor: 3.090

2.  Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.

Authors:  Nancy Reau; Paul Y Kwo; Susan Rhee; Robert S Brown; Kosh Agarwal; Peter Angus; Edward Gane; Jia-Horng Kao; Parvez S Mantry; David Mutimer; K Rajender Reddy; Tram T Tran; Yiran B Hu; Abhishek Gulati; Preethi Krishnan; Emily O Dumas; Ariel Porcalla; Nancy S Shulman; Wei Liu; Suvajit Samanta; Roger Trinh; Xavier Forns
Journal:  Hepatology       Date:  2018-07-25       Impact factor: 17.425

3.  The impact of hepatitis B infection on outcome of kidney transplantation: a long-term study.

Authors:  B Einollahi; S M Alavian; M Lessan-Pezeshki; N Simforoosh; M H Nourbala; Z Rostami; V Pourfarziani; E Nemati; M Sharafi; M Nafar; F Pour-Reza Gholi; A Firoozan
Journal:  Int J Organ Transplant Med       Date:  2010
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.